190 related articles for article (PubMed ID: 2110814)
1. Bioreductive drugs and the selective induction of tumour hypoxia.
Bremner JC; Stratford IJ; Bowler J; Adams GE
Br J Cancer; 1990 May; 61(5):717-21. PubMed ID: 2110814
[TBL] [Abstract][Full Text] [Related]
2. Comparing the anti-tumor effect of several bioreductive drugs when used in combination with photodynamic therapy (PDT).
Bremner JC; Bradley JK; Adams GE; Naylor MA; Sansom JM; Stratford IJ
Int J Radiat Oncol Biol Phys; 1994 May; 29(2):329-32. PubMed ID: 8195028
[TBL] [Abstract][Full Text] [Related]
3. Induction of tumour hypoxia by FAA and TNF: interaction with bioreductive drugs.
Edwards HS; Bremner JC; Stratford IJ
Int J Radiat Biol; 1991; 60(1-2):373-7. PubMed ID: 1677997
[No Abstract] [Full Text] [Related]
4. Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: with particular reference to in vivo methods of evaluation.
Bremner JC
Cancer Metastasis Rev; 1993 Jun; 12(2):177-93. PubMed ID: 8375020
[TBL] [Abstract][Full Text] [Related]
5. The effects of three bioreductive drugs (mitomycin C, RSU-1069 and SR4233) on cell lines selected for their sensitivity to mitomycin C or ionising radiation.
Keohane A; Godden J; Stratford IJ; Adams GE
Br J Cancer; 1990 May; 61(5):722-6. PubMed ID: 2110815
[TBL] [Abstract][Full Text] [Related]
6. Bioreductive drugs as post-irradiation sensitizers: comparison of dual function agents with SR 4233 and the mitomycin C analogue EO9.
Adams GE; Stratford IJ; Edwards HS; Bremner JC; Cole S
Int J Radiat Oncol Biol Phys; 1992; 22(4):717-20. PubMed ID: 1544844
[TBL] [Abstract][Full Text] [Related]
7. Bioreductive drugs in cancer therapy.
Stratford IJ
BJR Suppl; 1992; 24():128-36. PubMed ID: 1341908
[No Abstract] [Full Text] [Related]
8. Enhancement of chemotherapy and nitroimidazole-induced chemopotentiation by the vasoactive agent hydralazine.
Siemann DW
Br J Cancer; 1990 Sep; 62(3):348-53. PubMed ID: 2206941
[TBL] [Abstract][Full Text] [Related]
9. Increasing the effect of photodynamic therapy on the RIF-1 murine sarcoma, using the bioreductive drugs RSU1069 and RB6145.
Bremner JC; Adams GE; Pearson JK; Sansom JM; Stratford IJ; Bedwell J; Bown SG; MacRobert AJ; Phillips D
Br J Cancer; 1992 Dec; 66(6):1070-6. PubMed ID: 1457346
[TBL] [Abstract][Full Text] [Related]
10. Induction of tumour hypoxia post-irradiation: a method for increasing the sensitizing efficiency of misonidazole and RSU 1069 in vivo.
Stratford IJ; Adams GE; Godden J; Howells N
Int J Radiat Biol; 1989 Mar; 55(3):411-22. PubMed ID: 2564037
[TBL] [Abstract][Full Text] [Related]
11. Manipulation of oxygenation in a human tumour xenograft with BW12C or hydralazine: effects on responses to radiation and to the bioreductive cytotoxicity of misonidazole or RSU-1069.
Cole S; Robbins L
Radiother Oncol; 1989 Nov; 16(3):235-43. PubMed ID: 2587812
[TBL] [Abstract][Full Text] [Related]
12. Induction of hypoxia in the KHT sarcoma by tumour necrosis factor and flavone acetic acid.
Edwards HS; Bremner JC; Stratford IJ
Int J Radiat Biol; 1991 Feb; 59(2):419-32. PubMed ID: 1671692
[TBL] [Abstract][Full Text] [Related]
13. Hypoxic sensitizer and cytotoxin for head and neck cancer.
Lee DJ; Moini M; Giuliano J; Westra WH
Ann Acad Med Singap; 1996 May; 25(3):397-404. PubMed ID: 8876907
[TBL] [Abstract][Full Text] [Related]
14. Tirapazamine administered as a neoadjuvant to radiotherapy reduces metastatic dissemination.
Lunt SJ; Telfer BA; Fitzmaurice RJ; Stratford IJ; Williams KJ
Clin Cancer Res; 2005 Jun; 11(11):4212-6. PubMed ID: 15930359
[TBL] [Abstract][Full Text] [Related]
15. Unusual oxygen concentration dependence of toxicity of SR-4233, a hypoxic cell toxin.
Koch CJ
Cancer Res; 1993 Sep; 53(17):3992-7. PubMed ID: 8358728
[TBL] [Abstract][Full Text] [Related]
16. Use of the comet assay to detect hypoxic cells in murine tumours and normal tissues exposed to bioreductive drugs.
Olive PL
Acta Oncol; 1995; 34(3):301-5. PubMed ID: 7779413
[TBL] [Abstract][Full Text] [Related]
17. Manipulation of radiobiological hypoxia in a human melanoma xenograft to exploit the bioreductive cytotoxicity of RSU-1069.
Cole S; Stratford IJ; Adams GE
Int J Radiat Biol; 1989 Nov; 56(5):587-91. PubMed ID: 2573651
[No Abstract] [Full Text] [Related]
18. Potentiation of the anti-tumour effect of melphalan by the vasoactive agent, hydralazine.
Stratford IJ; Adams GE; Godden J; Nolan J; Howells N; Timpson N
Br J Cancer; 1988 Aug; 58(2):122-7. PubMed ID: 3166900
[TBL] [Abstract][Full Text] [Related]
19. The effect of low pH and hypoxia on the cytotoxic effects of SR4233 and mitomycin C in vitro.
Skarsgard LD; Vinczan A; Skwarchuk MW; Chaplin DJ
Int J Radiat Oncol Biol Phys; 1994 May; 29(2):363-7. PubMed ID: 8195034
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent.
Patterson LH; McKeown SR; Ruparelia K; Double JA; Bibby MC; Cole S; Stratford IJ
Br J Cancer; 2000 Jun; 82(12):1984-90. PubMed ID: 10864207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
